Related Experiment Video
Updated: Jun 14, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients
Alex E Henney1,2,3, David R Riley1,2, Theresa J Hydes1,2,3
1Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
Introduction:
The cumulative impact of metabolic syndrome (MetS) components on micro- and macrovascular disease in metabolic dysfunction-associated steatotic liver disease (MASLD) is unclear. We aimed to determine whether the number of the MetS components increases the risk of micro- and macrovascular disease in patients with MASLD.
Methods:
We performed a retrospective cohort study of electronic medical records using the TriNetX network, a global federated database. The exposure arm was patients with hepatic steatosis (defined via International Classification of Diseases, 10th Revision coding, or modified hepatic steatosis index), and ≥1 MetS components (obesity/central adiposity, insulin resistance, hypertension, or dyslipidaemia), compared with a reference arm of adults without any MetS components or hepatic steatosis. Our propensity score matched (1:1) for confounders with 5 years of follow-up. Primary outcomes included microvascular (peripheral neuropathy, retinopathy, and nephropathy) and macrovascular (cardiovascular events, cerebrovascular accidents, and peripheral vascular disease) disease. Secondary analyses assessed the impact of additional MetS components on these outcomes, as well as the impact of sex.
Results:
MASLD, defined by hepatic steatosis and insulin resistance (n = 15 937), carried the highest risk of microvascular disease (HR 13.93 (95% CI 8.55-22.68)), whilst MASLD, defined by hepatic steatosis and hypertension (n = 53 028), carried the highest risk of macrovascular disease (7.23 (6.45-8.13)). MASLD with all MetS components carried greatest risk of both micro- (31.20 (28.88-33.70) (n = 462 789)) and macrovascular (8.04 (7.33-8.82) (n = 336 010)) disease.
Conclusion:
We demonstrate a differential effect of MetS components on micro- and macrovascular disease risk in patients with MASLD, with a cumulative impact of multiple MetS on overall risk. The impact of MetS components was most pronounced in women. Aggressive metabolic risk factor management is critical for prevention of micro- and macrovascular complications.
Insights
Metabolic dysfunction-associated steatotic liver disease (MASLD) increases micro- and macrovascular disease risk, especially with more metabolic syndrome (MetS) components. This risk is highest in women, highlighting the need for aggressive management.
Area of Science:
- Hepatology
- Cardiology
- Endocrinology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent.
- The combined effect of metabolic syndrome (MetS) components on vascular complications in MASLD patients remains unclear.
- Understanding these risks is crucial for patient management and preventative strategies.
Purpose of the Study:
- To investigate the association between the number of MetS components and the risk of micro- and macrovascular diseases in patients with MASLD.
- To determine the differential impact of specific MetS components on vascular outcomes.
- To explore the influence of sex on these associations.
Main Methods:
- Retrospective cohort study using the TriNetX global federated database.
- Patients with hepatic steatosis and at least one MetS component were compared to a control group without these conditions.
- Propensity score matching and 5-year follow-up were employed to analyze microvascular and macrovascular outcomes.
Main Results:
- MASLD with insulin resistance showed the highest risk for microvascular disease (HR 13.93).
- MASLD with hypertension demonstrated the highest risk for macrovascular disease (HR 7.23).
- MASLD with all MetS components presented the greatest risk for both microvascular (HR 31.20) and macrovascular (HR 8.04) diseases, with a pronounced effect in women.
Conclusions:
- The number of MetS components significantly increases micro- and macrovascular disease risk in MASLD patients.
- Specific MetS components have differential effects on micro- and macrovascular complications.
- Aggressive management of metabolic risk factors is essential for preventing vascular complications in MASLD, particularly in women.
More Related Videos
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
10:31An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
Published on: April 20, 2018
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Obesity
Cholesterol: Significance and Regulation
Considering cholesterol and...
Diabetes: Symptoms, Diagnosis, and Complications